Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence

2.1 Abemaciclib (Verzenios, Eli Lilly) 'in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. In pre- or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist'.

2.2 The dosage schedule is available in the summary of product characteristics for abemaciclib.

2.3 The list price for abemaciclib is £2,950 per 28‑day cycle of 150‑mg tablets (£1,475 per 28‑tablet pack or £2,950 per 56‑tablet pack; excluding VAT; BNF online, accessed May 2022).

2.4 The company has a commercial arrangement. This makes abemaciclib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.